摘要
目的:观察FOLFIRI方案二线治疗晚期结直肠癌的疗效及安全性。方法:28例FOLFOX4化疗失败的患者,改用FOLFIRI方案挽救化疗。结果:完全缓解为0例,部分缓解6例,稳定16例,进展6例,有效率21.4%。不良反应主要为恶心、呕吐、白细胞减少和延迟性腹泻。结论:FOLFIRI方案二线治疗晚期结直肠癌,疗效肯定,不良反应可控制。
OBJECTIVE： To observe the clinic efficacy and safety of FOLFIRI as a second line treatment for patients with advanced colorectal cancer. METHODS： Twenty - eight patients with advanced colorectal cancer whose disease progressed after first treatment with FOLFOX4 were included to receive the second line treatment with FOLFIRI regimen. RESULTS： Of the total 28 cases, 0 had complete response, 6 partial response, 16 stable disease, 6 progressive disease, and the responsive rate was 21.4%. The majority of adverse reaction was nausea, vomiting, leucopenia and tardive diarrhea. CONCLUSION： As a second line therapy, FOLFIRI has a confirmed therapeutic response and tolerable toxicity in patients with advanced colorectal cancer.
出处
《中国药房》
CAS
CSCD
北大核心
2008年第23期1812-1813,共2页
China Pharmacy
关键词
伊立替康
氟尿嘧啶
亚叶酸钙
晚期结直肠癌
化学治疗
Irinotecan
Fluorouracil
Calcium folinate
Advanced colorectal cancer
Chemotherapy
